MMJ Recs

DECEMBER 28, 2023

In recent years, a significant shift has occurred in the perception of medical marijuana, transforming it from a controversial substance to a recognized and, in some places, a legal form of medical treatment. CBD, a non-psychoactive cannabinoid, has gained attention for its anti-anxiety effects.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. minor cannabinoids market size is expected to reach USD 26.2

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Puff Puff Post

JANUARY 1, 2020

One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Cannabis Law Report

JULY 27, 2021

and its Scientific Advisory Board, the Organization Publishes New Real-World Study on Epilepsy and CBD. –(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Puff Puff Post

JANUARY 1, 2020

One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids. Cannabinoids even alleviate certain types of pain that opiates don’t always treat well.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . What can the current clinical trials tell us?

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events.

Safety 52

Safety Cannabinoids Events Data 52

United Patients Group

JANUARY 8, 2023

Cannabis has also been used for centuries to treat gastrointestinal disorders, epilepsy, rheumatism and malaria. Cannabis has been shown to be an effective treatment for a variety of conditions caused by bacteria, viruses and fungi. This is because it contains cannabinoids, which have anti-inflammatory properties.

Blood Pressure 105

Blood Pressure Sleep Cannabinoids Clinical Trials 105

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. The study examines the effect of the cannabinoid Cannabidivarin, more commonly referred to as CBDV , on irritability and repetitive behaviors in children with autism spectrum disorder.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Canna Care Docs

JUNE 18, 2018

CBD is one of close to 85 cannabinoids present in cannabis, with THC being the most commonly known. Cannabinoids are chemicals within cannabis that offer relief to patients, similar to natural compounds in our body called endocannabinoids. Epilepsy Currents. CBD-enriched medical cannabis for intractable pediatric epilepsy.

Clinical Trials 75

Clinical Trials CBD Epilepsy Patients 75

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

The Cannigma

MAY 19, 2021

In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. In 2018, Epidolex became the first plant-derived cannabinoid prescription medicine to receive FDA approval. Shutterstock).

Law 137

Law Legalization Clinical Trials CBD 137

The Joint Blog

JANUARY 31, 2021

The study is titled A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extract as complementary therapy: A case report. For the study researchers studied the effects of marijuana extracts in a fifteen-year-old who suffered from autism, anxiety, and controlled epilepsy. ml twice daily.

Epilepsy 62

Epilepsy Extraction Research and Development Clinical Trials 62

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. Food and Drug Administration (FDA) had approved only three cannabinoid-based medicines. Prior to this week, the U.S. Epidiolex contains less than 0.1

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

The Joint Blog

JANUARY 23, 2020

Marijuana may be use “in the treatment of a range of psychiatric disorders”, according to a new study published in the journal BMC Psychiatry. The study is titled “Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.”

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

Veriheal

APRIL 11, 2022

We could potentially develop north of 11,000 drugs that are cannabinoid-based. In particular, of all the components contained in the cannabis plant— including cannabinoids , terpenes , and flavonoids — the cannabis compound tetrahydrocannabinol (THC) has proven to harbor medicinal benefits when used in specific formulations.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

NOVEMBER 29, 2019

For instance, THC has shown the potential to help in the treatment of conditions like PTSD, depression, eating disorders, and epilepsy. When a person uses a THC oil pen ( vapingdaily gives more details) to ingest this cannabinoid, it can benefit them in different ways. However, cannabinoids use modulation.

Oil 104

Oil THC Cannabinoids Research and Development 104

Cannabis Law Report

AUGUST 26, 2019

Over the years, research has generated results to suggest that marijuana benefits in the treatment of some conditions. The review found that marijuana, or products having cannabinoids are effective at relieving chronic pain. The approval is based on the research and clinical trials. Let us have a look at those.

Chronic Pain 45

Chronic Pain Clinical Trials Epilepsy Conditions 45

Cannabis Law Report

DECEMBER 1, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

MMJ Recs

DECEMBER 22, 2023

The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment. Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

DECEMBER 28, 2021

This is all thanks to CBD, or cannabidiol, one of the most important cannabinoids identified in cannabis plants. But what makes CBD different from other cannabinoids is its therapeutic properties. This is because Epidiolex has been proven an effective treatment after going through various clinical trials.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

CannaMD

AUGUST 8, 2020

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system.

CBD 100

CBD DEA Research and Development Hemp 100

Cannabis Law Report

OCTOBER 19, 2021

MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Canna Care Docs

DECEMBER 16, 2020

It would feel like an out-of-body experience, except for one fact: your body is constantly reminding you of those symptoms you’ve been suffering from all this time, putting treatment on the back burner while you deal with life as we know it. In several clinical studies, marijuana use seemed to improve mood for those with reactive depression.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

NOVEMBER 24, 2019

Severe treatment-resistant epilepsy. Consider nabilone as an add-on treatment for adults (18 years and over) with chemotherapy-induced nausea and vomiting which persists with optimised conventional antiemetics. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. Recommendations.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 98

CBD THC Conditions Medicine 98

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Epidiolex is a CBD-infused oral-based medication designed to help patients as young as two-years-old treat epilepsy disorders.

Research and Development 40

Research and Development Epilepsy Clinical Trials Treatment 40

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

The first-ever cannabis-based drug with FDA approval is Epidiolex*, a new prescription drug designed to treat severe seizure disorders that do not respond to other treatments. GW Pharma carefully developed Epidiolex using cannabinoids to reduce the occurrence of seizures. Medical Marijuana In Pill Form, With FDA Approval.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

The Cannigma

AUGUST 26, 2021

According to the Commonwealth Department of Health , Nabiximols (a cannabinoid spray marketed as Sativex) is the only cannabis product that is considered a registered medicine in the country. No cannabis products are subsidized through the Pharmaceutical Benefits Scheme (PBS), and the price is set by the supplier. Costs of medical marijuana.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Greencamp

AUGUST 16, 2018

Exploring the available research on ALS and cannabinoids. The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies).

Strains 94

Strains Cannabinoids Research and Development Indica 94

Veriheal

AUGUST 31, 2020

Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

CannaTech

SEPTEMBER 16, 2018

But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression. Cannabis medicine presents itself as an intimidating option despite patients requesting it as a form of treatment.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

FEBRUARY 3, 2022

The combined effects of both cannabinoids (THC and CBD) have their health advantages, but when taken at once. The oil segment is accounted to have the largest share in global cannabis treatment market during the forecast period. Growing Adoption of Medical Cannabis for the Treatment of Chronic Compounds. Impact Factor Analysis.

Indica 52

Indica Oil Legalization Research and Development 52